Advertisement
Letter to the Editor| Volume 144, P392-394, February 2021

Download started.

Ok

Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al

Published:December 03, 2020DOI:https://doi.org/10.1016/j.ejca.2020.09.041
Comment on: ‘Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer’ by De Vincentis et al
Previous ArticleCardiac magnetic resonance imaging of transient myocardial dysfunction in a patient treated with checkpoint-targeted immunotherapy
Next ArticleResponse to comment on “Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer”
      We were very impressed by the interesting and intriguing work of van der Doelen et al. [
      • van der Doelen M.J.
      • Isaacsson Velho P.
      • Slootbeek P.H.J.
      • Pamidimarri Naga S.
      • Bormann M.
      • van Helvert S.
      • et al.
      Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
      Eur J Canc. 2020; 136 (Oxford, England : 1990): 16-24https://doi.org/10.1016/j.ejca.2020.05.001
      ] recently published in your Journal . This inspires some considerations that we would gladly share with the scientific community.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • van der Doelen M.J.
        • Isaacsson Velho P.
        • Slootbeek P.H.J.
        • Pamidimarri Naga S.
        • Bormann M.
        • van Helvert S.
        • et al.
        Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer.
        Eur J Canc. 2020; 136 (Oxford, England : 1990): 16-24https://doi.org/10.1016/j.ejca.2020.05.001
        View in Article
        • Terrisse S.
        • Karamouza E.
        • Parker C.C.
        • Sartor A.O.
        • James N.D.
        • Pirrie S.
        • et al.
        Overall survival in men with bone metastases from castration-resistant prostate cancer treated with bone-targeting radioisotopes: a meta-analysis of individual patient data from randomized clinical trials.
        JAMA Oncol. 2020; 6: 206-216https://doi.org/10.1001/jamaoncol.2019.4097
        View in Article
        • Ricci M.
        • Frantellizzi V.
        • Bulzonetti N.
        • De Vincentis G.
        Reversibility of castration resistance status after Radium-223 dichloride treatment: clinical evidence and Review of the literature.
        Int J Radiat Biol. 2018; : 1-29https://doi.org/10.1080/09553002.2019.1558301
        View in Article
        • Casarin S.
        • Dondossola E.
        An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.
        BMC Canc. 2020; 20: 605https://doi.org/10.1186/s12885-020-07084-w
        View in Article
        • Antonarakis E.S.
        • Lu C.
        • Luber B.
        • Liang C.
        • Wang H.
        • Chen Y.
        • et al.
        Germline DNA-repair gene mutations and outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.
        Eur Urol. 2018; 74: 218-225https://doi.org/10.1016/j.eururo.2018.01.035
        View in Article
        • Isaacsson Velho P.
        • Qazi F.
        • Hassan S.
        • Carducci M.A.
        • Denmeade S.R.
        • Markowski M.C.
        • et al.
        Efficacy of radium-223 in bone-metastatic castration-resistant prostate cancer with and without homologous repair gene defects.
        Eur Urol. 2019; 76: 170-176https://doi.org/10.1016/j.eururo.2018.09.040
        View in Article
        • De Vincentis G.
        • Follacchio G.A.
        • Frantellizzi V.
        • Liberatore M.
        • Monteleone F.
        • Cortesi E.
        Prostate-specific antigen flare phenomenon during 223Ra-dichloride treatment for bone metastatic castration-resistant prostate cancer: a case report.
        Clin Genitourin Canc. 2016; 14: e529-e533https://doi.org/10.1016/j.clgc.2016.04.014
        View in Article
        • Morris M.J.
        • Loriot Y.
        • Sweeney C.J.
        • Fizazi K.
        • Ryan C.J.
        • Shevrin D.H.
        • et al.
        Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial.
        Eur J Canc. 2019; 114 (Oxford, England : 1990): 107-116https://doi.org/10.1016/j.ejca.2019.04.007
        View in Article
        • Frantellizzi V.
        • Costa R.
        • Mascia M.
        • Spanu A.
        • Farcomeni A.
        • Licari M.
        • et al.
        Primary radical prostatectomy or ablative radiotherapy as protective factors for patients with mCRPC treated with radium-223 dichloride: an Italian multicenter study.
        Clin Genitourin Canc. 2020; 18: 185-191https://doi.org/10.1016/j.clgc.2019.10.009
        View in Article
        • Frantellizzi V.
        • Monari F.
        • Mascia M.
        • Costa R.
        • Rubini G.
        • Spanu A.
        • et al.
        Validation of the 3-variable prognostic score (3-PS) in mCRPC patients treated with (223)Radium-dichloride: a national multicenter study.
        Ann Nucl Med. 2020; https://doi.org/10.1007/s12149-020-01501-7
        View in Article

      Article info

      Publication history

      Published online: December 03, 2020
      Accepted: September 26, 2020
      Received in revised form: September 17, 2020
      Received: August 13, 2020

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2020.09.041

      Copyright

      © 2020 Elsevier Ltd. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      Linked Article

      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX